Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF G469V |
| Therapy | Osimertinib |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF G469V | lung adenocarcinoma | sensitive | Osimertinib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Tagrisso (osimertinib) treatment inhibited viability of cells derived from a patient-derived xenograft (PDX) model of lung adenocarcinoma harboring BRAF G469V in culture and led to inhibition of tumor growth in a patient-derived xenograft (PDX) model (PMID: 34648945). | 34648945 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (34648945) | Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors. | Full reference... |